-ph. Eur.- Monograph Tablets -0478-: European Pharmacopoeia

Monograph 0478 defines tablets as solid pharmaceutical dosage forms containing a single dose of one or more active substances. They are generally obtained by compressing uniform volumes of particles or by other specialized manufacturing techniques like extrusion or molding.

A central purpose of Ph. Eur. 0478 is defining the physical tests that finished batches must satisfy. The monograph cross-references vital technical chapters to govern structural durability and mass reproducibility: The Ph.Eur. approach to tablet splitting

Use Ph. Eur. Monograph 0478 as your minimum quality standard for uncoated and film-coated immediate-release tablets. For regulatory submissions (e.g., CEP, DMF, or marketing authorization in Europe), you must comply with it. However, to achieve robust product quality, supplement it with: European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

“Patient acceptability,” argued Marta, the clinical liaison, “is twofold — safety and usability. Faster disintegration for children reduces choking risk and improves dosing accuracy.”

: Modified-release formulations engineered to resist gastric fluid and release the API within the intestinal tract. approach to tablet splitting Use Ph

The "Tablets -0478-" monograph is a general monograph that applies to all tablets, unless a specific monograph exists for a particular product. This monograph was introduced to provide a comprehensive framework for the evaluation of tablets, taking into account their physical, chemical, and microbiological properties.

💡 Monograph 0478 is the blueprint that ensures a tablet is more than just compressed powder—it is a sophisticated delivery system designed for precision and patient safety. pending regulatory approval. For dissolution

Designed to resist gastric fluid for 2–3 hours but disintegrate in intestinal fluid within 60 minutes.

: Finished with layers of resins, sugars, or polymers (film-coated) to protect the core or mask taste.

Depending on the tablet type, the monograph requires testing of (how fast it breaks down) or Dissolution (how fast the drug is released). An EDQM FAQ clarifies that the applicant may use the monograph’s prescribed disintegration test or develop their own, pending regulatory approval. For dissolution, Ph. Eur. general chapter 2.9.3 (Dissolution test for solid dosage forms) is the key reference.

Monograph 0478 defines tablets as solid pharmaceutical dosage forms containing a single dose of one or more active substances. They are generally obtained by compressing uniform volumes of particles or by other specialized manufacturing techniques like extrusion or molding.

A central purpose of Ph. Eur. 0478 is defining the physical tests that finished batches must satisfy. The monograph cross-references vital technical chapters to govern structural durability and mass reproducibility: The Ph.Eur. approach to tablet splitting

Use Ph. Eur. Monograph 0478 as your minimum quality standard for uncoated and film-coated immediate-release tablets. For regulatory submissions (e.g., CEP, DMF, or marketing authorization in Europe), you must comply with it. However, to achieve robust product quality, supplement it with:

“Patient acceptability,” argued Marta, the clinical liaison, “is twofold — safety and usability. Faster disintegration for children reduces choking risk and improves dosing accuracy.”

: Modified-release formulations engineered to resist gastric fluid and release the API within the intestinal tract.

The "Tablets -0478-" monograph is a general monograph that applies to all tablets, unless a specific monograph exists for a particular product. This monograph was introduced to provide a comprehensive framework for the evaluation of tablets, taking into account their physical, chemical, and microbiological properties.

💡 Monograph 0478 is the blueprint that ensures a tablet is more than just compressed powder—it is a sophisticated delivery system designed for precision and patient safety.

Designed to resist gastric fluid for 2–3 hours but disintegrate in intestinal fluid within 60 minutes.

: Finished with layers of resins, sugars, or polymers (film-coated) to protect the core or mask taste.

Depending on the tablet type, the monograph requires testing of (how fast it breaks down) or Dissolution (how fast the drug is released). An EDQM FAQ clarifies that the applicant may use the monograph’s prescribed disintegration test or develop their own, pending regulatory approval. For dissolution, Ph. Eur. general chapter 2.9.3 (Dissolution test for solid dosage forms) is the key reference.